Back to News
Market Impact: 0.15
I-Mab Appoints Charles Silberstein as Chief Financial Officer Effective November 2, 2026
Source: Nasdaq
Management & GovernanceHealthcare & Biotech
I-Mab, filing as NovaBridge Biosciences, appointed Charles “Chuck” Silberstein, M.D., M.B.A., CFA, as CFO effective November 2, 2026. He succeeds Ming (Kyler) Lei, who tendered his resignation; the available article text provides no further details or financial implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
NBP0.10
More News
- FedEx beats expectations, raises outlook in first report since calendar adjustment
- Warsh says politics played no role in Fed’s rate decision by group he is ’honored’ to lead
- Tencent’s Cloud Boss Plays Long Game to Patch ‘Leaky’ AI Ship
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- ECB to hold rates as investors focus on French bonds, Lagarde’s future
- Microsoft reveals strong cloud growth amid financial reporting overhaul